key: cord-1056173-l0acym2l authors: Martínez-Roca, Alexandra; Rodríguez-Lobato, Luis Gerardo; Dot, Nuria Ballestar; Miralles, Cristina Gallego; Fernández-Avilés, Francesc title: Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak date: 2021-04-24 journal: Leuk Res DOI: 10.1016/j.leukres.2021.106589 sha: cc45683f305d521d05e5a606d5d6ad4b25eb2f00 doc_id: 1056173 cord_uid: l0acym2l nan -SARS-CoV-2 health crisis forced institutions to place a hold on most non-priority healthcare activities. -At-home autologous stem cell transplant may present as an option to continue to perform this procedure. -At-home autologous stem cell transplant presents as a safe option for patients in a pandemic state. The unusual scenario presented, as well as the fragile state of our immunocompromised patients due to hematological diseases and administered treatments (2) obligated us to cease and delay cancer treatments and procedures. Our hospital transplant unit includes eight beds, with a median (range) of 11 (7) (8) (9) (10) (11) (12) (13) (14) (15) patients admitted daily. It forms part of the total 32 beds assigned to hematological patients. Since November 2000, 419 at-home autologous stem cell transplants (ASCT) have been performed, with a median of 32 ASCT per year within the last ten years. These transplants include patients with multiple myeloma (MM) and lymphoma. The program experience and its improvements have been published elsewhere (3-6), showing its feasibility and safety, as well as reproducibility in other hematological centers. J o u r n a l P r e -p r o o f As such, when the national lockdown took place in Spain, at-home ASCT continued. However, new policies and adjustments were introduced to personalize the procedure in such a state of affairs. Herein we describe our experience and optimization strategies undertaken in our "home transplant unit" to uphold patient safety during the procedure. Although SARS-CoV-2 continues to pose a burden on many health systems worldwide, our model may provide insight on how to improve transplant units without compromising patient care. Similarly, extensive and rigorous health education was provided to both patient and caregiver before admission to the at-home ASCT program. In cases in which patients had only one caregiver, a mandatory NPS was required before the patient could be discharged to a residence. Caregivers were advised to quarantine after negative NPS results and during the entirety of the procedure. To avoid caregiver exposure, logistical support was integrated by either a patient's relatives or volunteers offered by our unit. Patients with more than one co-inhabitant were advised to be confined alone in one bedroom and adopt protective, necessary measures (a FFP2 face mask without exhalation valve, hand hygiene, and protective reverse isolation) when sharing common household areas. Hematology nurses followed patients on a daily basis, either at home or by phone. During the 30-day follow-up period of an at-home ASCT, a patient with Hodgkin lymphoma required hospital readmission on day +18 due to septic shock by Serratia marcescens-producing AmpC enzymes encoded by resident chromosomal genes (cAmpCs). The patient required vasopressors and broad-spectrum antibiotics but was able to fully recover and return home ten days after admission. Finally, none of the patients presented with disease progression or relapse during the follow-up period. One patient with MM did undergo a second at-home ASCT due to a high-risk cytogenetic disease, while four patients began maintenance therapy. This study addresses the different challenges in performing at-home ASCT during respectively. For most cancers, data suggests that treatment postponement is associated with worst overall survival (12) , even though no specific data is present concerning hematological patients or cellular therapy recipients. We believe, as some other publications already confirm, that patients with hematological malignancies receiving HSCT or cellular therapy cannot experience a delay in therapy (13) . We acknowledge that many medical, logistical and social elements must be taken into account before an HSCT can be performed, especially in a state of pandemic. However, we also believe that the ability to perform at-home ASCT guarantees that treatment times are respected to some extent, while upholding patient safety. This study has some limitations, including that it was carried out in a single center with a low number of patients. We recognize that our ability to continue with at-home ASCT was in part due to our vast, 20-year experience of performing such a procedure. Currently, as we face a second SARS-CoV-2 wave across Europe, with growing numbers of hospitalized patients once again, our main challenge will be to maintain scheduled hematological treatments and procedures and ensuring patient care. That stated, the at-home ASCT could serve as a safe and reproducible option to perform. Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever At-Home HSCT At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: A comparative study European Society for Blood and Marrow Transplantation (EBMT) Interim guidelines for COVID-19 management in hematopoietic cell transplant and cellular therapy patients Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States Figure 1. HSCT activity. March 13 th to May 25 th Abbreviations: Allo-HSCT: allogeneic hematopoietic stem cell transplant; ASCT: autologous hematopoietic stem cell transplantation. Inpatient At-home